(Reuters) - arGEN-X BV :

* arGEN-X expands preclinical pipeline with ARGX-115, anovel simple antibody for cancer immunotherapy

* Has exercised its option to exclusively license a preclinical therapeutic antibody candidate, now ARGX-115, totarget GARP, a novel immune checkpoint with potential in cancerimmunotherapySource text for Eikon: Further company coverage: (Gdynia Newsroom)